Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: A qualitative study

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Singh, Jasvinder A ^a,b,c  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; ANTIGOUT AGENT; THIAZOLE DERIVATIVE; URIC ACID;

ABDOMINAL PAIN; ADULT; AFRICAN AMERICAN; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DISEASE SEVERITY; DROWSINESS; DYSPHAGIA; ERUCTATION; FEMALE; GASTRITIS; GOUT; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NAUSEA; PATIENT PREFERENCE; PHYSICIAN; PILL; PRESCRIPTION; QUALITATIVE ANALYSIS; QUALITATIVE RESEARCH; TASTE DISORDER; TRUST; VOMITING; AGED; ATTITUDE TO HEALTH; BLOOD; EVALUATION STUDY; INFORMATION PROCESSING; PSYCHOLOGY;

AFRICAN AMERICANS; AGED; ALLOPURINOL; EVALUATION STUDIES AS TOPIC; FEBUXOSTAT; FEMALE; FOCUS GROUPS; GOUT; GOUT SUPPRESSANTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; THIAZOLES; URIC ACID;

EID: 84899082752     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4524     Document Type: Article

References (39)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011, 63:3136-3141. 10.1002/art.30520, 21800283.
2. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81:925-934. 10.4065/81.7.925, 16835972.
3. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007, 57:822-829. 10.1002/art.22767, 3619972, 17530682.
4. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, Chan KA, Roblin D, Raebel MA, Von Worley A, Platt R, Saag KG. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 2006, 65:1368-1372. 10.1136/ard.2006.051649, 1798311, 16644784.
5. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004, 51:321-325. 10.1002/art.20405, 15188314.
6. Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009, 48:188-194.
7. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009, 36:1273-1282. 10.3899/jrheum.080814, 19286847.
8. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 2008, 27:585-591. 10.1080/15257770802136032, 18600509.
9. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61-65. 10.1097/01.rhu.0000209882.50228.9f, 16601538.
10. Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009, 15:3-7. 10.1097/RHU.0b013e3181945d2c, 19125135.
11. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012, 64:1431-1446. 10.1002/acr.21772, 3683400, 23024028.
12. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324. 10.1136/ard.2006.055269, 1798308, 16707532.
13. Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009, 68:1265-1270. 10.1136/ard.2008.092619, 18701554.
14. Harrold LR, Mazor KM, Peterson D, Naz N, Firneno C, Yood R. Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord 2012, 13:180. 10.1186/1471-2474-13-180, 3517442, 22995041.
15. Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn 2010, 6:263-271. 10.1177/1742395310378761, 3134238, 20675361.
16. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 2012, 71:1490-1495. 10.1136/annrheumdis-2011-200801, 22440822.
17. Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol 2008, 35:498-501.
18. Coley K, Saul M, Pater K. Relationship between race, uric acid levels, urate-lowering therapy and resource use in patients with gout. Arthritis Rheum 2012, 64:S772.
19. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008, 67:609-613.
20. Fife BL. The conceptualization of meaning in illness. Soc Sci Med 1994, 38:309-316. 10.1016/0277-9536(94)90400-6, 8140457.
21. Lieban RW. From illness to symbol and symbol to illness. Soc Sci Med 1992, 35:183-188. 10.1016/0277-9536(92)90165-M, 1380738.
22. Montagne M. The metaphorical nature of drugs and drug taking. Soc Sci Med 1988, 26:417-424. 10.1016/0277-9536(88)90310-3, 3363393.
23. Charmaz K. Loss of self: a fundamental form of suffering in the chronically ill. Sociol Health Illn 1987, 5:168-195.
24. Corbin J, Strauss AL. Accompaniments of chronic illness: changes in body, self, biography, and biographical time. Research in the Sociology of Health Care: A Research Annual. Vol. 6. The Experience and Management of Chronic Illness Greenwich, Vol. 6 1987, 249-281. Greenwich, CT: JAI Press, Inc, Roth JA, Conrad P.
25. Corbin JM, Strauss AL. Experiencing body failure and a disrupted self image. Unending Work and Care: Managing Chronic Illness at Home 1988, 49-67. San Francisco, CA: Jossey-Bass, Corbin J, Strauss AL.
26. Lambert BL, Street RL, Cegala DJ, Smith H, Kurtz S, Schofield T. Provider-patient communication, patient-centered care, and the mangle of practice. Health Commun 1997, 9:27-43.
27. Miller D, Shewchuk R, Elliot TR, Richards S. Nominal group technique: a process for identifying diabetes self-care issues among patients and caregivers. Diabetes Educ 2000, 26:305-310. 312, 314, 10.1177/014572170002600211, 10865596.
28. Hegger MJ. A fresh approach to group goal setting. The three-way rotation nomimal group technique. J Nurs Staff Dev 1986, 2:13-17.
29. Gallagher M, Hares T, Spencer J, Bradshaw C, Webb I. The nominal group technique: a research tool for general practice?. Fam Pract 1993, 10:76-81. 10.1093/fampra/10.1.76, 8477899.
30. Jefferson WK, Zunker C, Feucht JC, Fitzpatrick SL, Greene LF, Shewchuk RM, Baskin ML, Walton NW, Phillips B, Ard JD. Use of the Nominal Group Technique (NGT) to understand the perceptions of the healthiness of foods associated with African Americans. Eval Program Plann 2010, 33:343-348. 10.1016/j.evalprogplan.2009.11.002, 20047762.
31. Kleiner-Fisman G, Gryfe P, Naglie G. A patient-based needs assessment for living well with Parkinson disease: implementation via nominal group technique. Parkinson's Dis 2013, 2013:974964. 3588173, 23476891.
32. MacLachlan M. Identifying problems in community health promotion: an illustration of the Nominal Group Technique in AIDS education. J R Soc Health 1996, 116:143-148. 10.1177/146642409611600303, 8691395.
33. Pastrana T, Radbruch L, Nauck F, Hover G, Fegg M, Pestinger M, Ross J, Krumm N, Ostgathe C. Outcome indicators in palliative care-how to assess quality and success. Focus group and nominal group technique in Germany. Support Care Cancer 2010, 18:859-868. 10.1007/s00520-009-0721-4, 3128732, 19701782.
34. Pena A, Estrada CA, Soniat D, Taylor B, Burton M. Nominal group technique: a brainstorming tool for identifying areas to improve pain management in hospitalized patients. J Hosp Med 2012, 7:416-420. 10.1002/jhm.1900, 22190453.
35. Redman S, Carrick S, Cockburn J, Hirst S. Consulting about priorities for the NHMRC national breast cancer centre: how good is the nominal group technique. Aust N Z J Public Health 1997, 21:250-256. 10.1111/j.1467-842X.1997.tb01695.x, 9270149.
36. Rosenstock IM. Why people use health services. Milbank Mem Fund Q 1966, 44:94-127. 10.2307/3348967, 5967464.
37. Granger BB, Ekman I, Granger CB, Ostergren J, Olofsson B, Michelson E, McMurray JJ, Yusuf S, Pfeffer MA, Swedberg K. Adherence to medication according to sex and age in the CHARM programme. Eur J Heart Fail 2009, 11:1092-1098. 10.1093/eurjhf/hfp142, 19875409.
38. Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt) 2014, 23:112-119. 10.1089/jwh.2012.3972, 24206025.
39. Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, Miller CL, Bangsberg DR, Hogg RS. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep 2011, 8:277-287.